Literature DB >> 27735031

Relationship between levels of inflammatory cytokines in the peripheral blood and the severity of depression and anxiety in patients with Parkinson's disease.

X-M Wang1, Y-G Zhang, A-L Li, Z-H Long, D Wang, X-X Li, J-H Xia, S-Y Luo, Y-H Shan.   

Abstract

OBJECTIVE: The present study aims to investigate the relationship between expression of inflammatory cytokines in the peripheral blood and the severity of depression and anxiety in patients with Parkinson's disease (PD). PATIENTS AND METHODS: Between January 2012 and December 2015, 62 PD patients admitted to our institution were included in the PD group, and 62 healthy subjects seeking health check-up at our institution during the same period of time were enrolled in the control group. Levels of inflammatory cytokines, including IL-1b, IL-6, interferon-g (INF-g), hypersensitive C-reactive protein (hsCRP) and soluble IL-2 receptor (sIL-2R), were measured by using Enzyme-linked immunosorbent assay (ELISA). Hamilton Depression Scale (HAMD) and Hamilton Anxiety Scale (HAMA) were used to assess the severity of depression and anxiety, respectively.
RESULTS: A total of 124 subjects were included into PD group and control group, 62 for each. No significant differences were observed in the gender, age, body mass index (BMI), smoking history and alcohol history between two groups (p > 0.05). Levels of IL-1b, IL-6, TNF-a, hsCRP and sIL-2R were significantly higher in patients of PD group than those in the control group (p < 0.05). HAMD and HAMA scores in PD group were significantly higher than those in the control group [(22.74 ± 6.34), (20.90 ± 5.86) vs. (2.17±3.46), (3.79 ± 3.55), p < 0.05]. HAMD and HAMA scores were positively correlated with the levels of TNF-a, hsCRP and sIL-2R in the peripheral blood of PD patients (p < 0.05).
CONCLUSIONS: Expression of inflammatory cytokines are elevated in the peripheral blood of PD patients, and the severity of depression and anxiety is correlated with levels of TNF-a, hsCRP and sIL-2R in the peripheral blood of these patients.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27735031

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  15 in total

Review 1.  Blood and Cerebrospinal Fluid Biomarkers of Inflammation in Parkinson's Disease.

Authors:  Milan Zimmermann; Kathrin Brockmann
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

Review 2.  Inflammatory markers and depression in Parkinson's disease: a systematic review.

Authors:  Luis Guilherme Ramanzini; Luís Fernando Muniz Camargo; Juliana Oliveira Freitas Silveira; Guilherme Vargas Bochi
Journal:  Neurol Sci       Date:  2022-08-30       Impact factor: 3.830

3.  Effects of long-term infliximab and tocilizumab treatment on anxiety-like behavior and cognitive function in naive rats.

Authors:  Frideriki Poutoglidou; Chryssa Pourzitaki; Maria Eleni Manthou; Foteini Malliou; Athanasios Saitis; Ioannis Tsimoulas; Spyridon Panagiotopoulos; Dimitrios Kouvelas
Journal:  Pharmacol Rep       Date:  2021-09-27       Impact factor: 3.024

4.  Non-Motor Symptoms of Parkinson's Disease: The Neurobiology of Early Psychiatric and Cognitive Dysfunction.

Authors:  Ayan Hussein; Christopher A Guevara; Pamela Del Valle; Swati Gupta; Deanna L Benson; George W Huntley
Journal:  Neuroscientist       Date:  2021-05-08       Impact factor: 7.235

Review 5.  An Integrative Approach to Neuroinflammation in Psychiatric disorders and Neuropathic Pain.

Authors:  Diana I Lurie
Journal:  J Exp Neurosci       Date:  2018-08-13

6.  C-Reactive Protein and Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis.

Authors:  Xiaohui Qiu; Yousheng Xiao; Jingjing Wu; Lu Gan; Yanning Huang; Jin Wang
Journal:  Front Neurol       Date:  2019-04-17       Impact factor: 4.003

7.  A bidirectional relationship between anxiety, depression and gastrointestinal symptoms in Parkinson's disease.

Authors:  Jacob D Jones; Brandon Dominguez; Joseph Bunch; Carmen Uribe; Yenny Valenzuela; Jonathan P Jacobs
Journal:  Clin Park Relat Disord       Date:  2021-08-10

8.  Inhibition of the hepatic Nlrp3 protects dopaminergic neurons via attenuating systemic inflammation in a MPTP/p mouse model of Parkinson's disease.

Authors:  Chen Qiao; Qian Zhang; Qingling Jiang; Ting Zhang; Miaomiao Chen; Yi Fan; Jianhua Ding; Ming Lu; Gang Hu
Journal:  J Neuroinflammation       Date:  2018-07-02       Impact factor: 8.322

Review 9.  α-Synuclein and Noradrenergic Modulation of Immune Cells in Parkinson's Disease Pathogenesis.

Authors:  Laura M Butkovich; Madelyn C Houser; Malú G Tansey
Journal:  Front Neurosci       Date:  2018-09-11       Impact factor: 4.677

10.  High Inflammatory Tendency Induced by Malignant Stimulation Through Imbalance of CD28 and CTLA-4/PD-1 Contributes to Dopamine Neuron Injury.

Authors:  Li Dong; Yu-Min Zheng; Xiao-Guang Luo; Zhi-Yi He
Journal:  J Inflamm Res       Date:  2021-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.